Advisory Committee on Immunization Practices: Meeting, 3096-3097 [E6-529]
Download as PDF
<![CDATA[
3096
Federal Register / Vol. 71, No. 12 / Thursday, January 19, 2006 / Notices
The proposed change may be
discussed at meetings of the Advisory
Board on Radiation and Worker Health
on January 9, 2006 (teleconference) and
January 24–26, 2006 in Oak Ridge, TN.
Only after the close of the public
comment period will NIOSH make a
final decision regarding the proposed
change.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: January 12, 2006.
Alvin Hall,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E6–538 Filed 1–18–06; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: January 10, 2006.
Alvin Hall,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention (CDC).
[FR Doc. E6–543 Filed 1–18–06; 8:45 am]
BILLING CODE 4163–18–P
Dated: January 10, 2006.
Alvin Hall,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E6–542 Filed 1–18–06; 8:45 am]
Centers for Disease Control and
Prevention
BILLING CODE 4163–18–P
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following federal
advisory committee meeting:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Portfolio
Review of Single Gene Disorders and
Disability
sroberts on PROD1PC70 with NOTICES
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting:
Name: Disease, Disability, and Injury
Prevention and Control Special Emphasis
Panel (SEP): Portfolio Review of Single Gene
Disorders and Disability.
Times and Dates: 9 a.m.–5 p.m., February
10, 2006 (Closed).
Place: National Center on Birth Defects and
Developmental Disabilities, CDC, 12
Executive Park Drive, Atlanta, GA 30329,
Telephone Number 404.498.3800.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters to be Discussed: The meeting will
include the review and discussion of the
Single Gene Disorders and Disability Team’s
strategies and activities.
For Further Information Contact: Esther
Sumartojo, Acting Associate Director for
Science and Public Health, National Center
on Birth Defects and Developmental
Disabilities, CDC, 1600 Clifton Road, NE.,
Mailstop E–87, Atlanta, GA 30333,
Telephone Number 404.498.3800.
VerDate Aug<31>2005
16:38 Jan 18, 2006
Jkt 208001
Developmental Disabilities, CDC, 1600
Clifton Road, NE., (E–86), Atlanta, Georgia
30333, telephone 404/498–3926, fax 404/
498–3550.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities for
both the CDC and Agency for Toxic
Substances and Disease Registry.
National Task Force on Fetal Alcohol
Syndrome and Fetal Alcohol Effect:
Meeting
Name: National Task Force on Fetal
Alcohol Syndrome and Fetal Alcohol Effect
(NTFFASFAE).
Times and Dates: 8:30 a.m.–4:30 p.m.,
February 16, 2006. 8:30 a.m.–1 p.m.,
February 17, 2006.
Place: Embassy Suites Hotel Buckhead,
3285 Peachtree Road, NE., Atlanta, Georgia
30305, telephone 404/261–7733, fax 404/
262–0522.
Status: Open to the public, limited only by
the space available. The meeting room
accommodates approximately 65 people.
Purpose: The Secretary is authorized by the
Public Health Service Act, section 399G (42
U.S.C. Section 280f, as added by Pub. L. 105–
392), to establish a NTFFASFAE to: (1) Foster
coordination among all governmental
agencies, academic bodies and community
groups that conduct or support Fetal Alcohol
Syndrome (FAS) and Fetal Alcohol Effect
(FAE) research, programs and surveillance;
and (2) to otherwise meet the general needs
of populations actually or potentially
impacted by FAS and FAE.
Matters to be Discussed: Agenda items
include: (1) Discussion of the Task Force’s
Post-Exposure working group activities; (2)
presentations regarding prevention initiatives
from other relevant health topics such as
tobacco use and HIV; (3) presentation and
discussion regarding evidence-based review
of FAS prevention strategies; (4) Task Force
next steps; (5) updates from the Interagency
Coordinating Committee on FAS, CDC, and
other federal agencies, and liaison members;
(6) and scheduling of the next meeting.
Agenda items are subject to change as
priorities dictate.
For Further Information Contact: Mary
Kate Weber, M.P.H., Executive Secretary,
National Center on Birth Defects and
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Committee on Immunization
Practices: Meeting
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC) announce
the following Federal committee
meeting.
Name: Advisory Committee on
Immunization Practices (ACIP).
Time and Date: 8 a.m.–6:15 p.m., February
21, 2006.
8 a.m.–5 p.m., February 22, 2006.
Place: Centers for Disease Control and
Prevention, 1600 Clifton Road, NE., Building
19, Room 232, Atlanta, Georgia 30333.
Status: Open to the public, limited only by
the space available.
Purpose: The committee is charged with
advising the Director, CDC, on the
appropriate uses of immunizing agents. In
addition, under 42 U.S.C. 1396s, the
committee is mandated to establish and
periodically review and, as appropriate,
revise the list of vaccines for administration
to vaccine-eligible children through the
Vaccines for Children (VFC) program, along
with schedules regarding the appropriate
periodicity, dosage, and contraindications
applicable to the vaccines.
Matters To Be Discussed: The agenda will
include discussions on Rotavirus Vaccine
which may include a possible VFC Vote;
Human Papillomavirus Vaccine; general
recommendations on immunization;
Influenza; Herpes Zoster Vaccine; Tetanus
Toxoid, Diphtheria Toxoid, and Acellular
Pertussis (Tdap) Vaccines; and departmental
updates.
Agenda items are subject to change as
priorities dictate.
For Further Information Contact: Demetria
Gardner, Epidemiology and Surveillance
Division, National Immunization Program,
CDC, 1600 Clifton Road, NE., (E–61), Atlanta,
Georgia 30333, telephone 404/639–8096, fax
404/639–8616.
E:\FR\FM\19JAN1.SGM
19JAN1
Federal Register / Vol. 71, No. 12 / Thursday, January 19, 2006 / Notices
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities for
both the CDC and ATSDR.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
3097
Food and Drug Administration
products are no longer marketed, and
Able Labs has requested that the
approval of the applications be
withdrawn.
[Docket No. 2006N–0010]
DATES:
Dated: January 10, 2006.
Alvin Hall,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E6–529 Filed 1–18–06; 8:45 am]
Able Laboratories, Inc.; Withdrawal of
Approval of 43 Abbreviated New Drug
Applications
FOR FURTHER INFORMATION CONTACT:
Florine P. Purdie, Center for Drug
Evaluation and Research (HFD–7), Food
and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301–594–
2041.
BILLING CODE 4163–18–P
The Food and Drug
Administration (FDA) is withdrawing
approval of 43 abbreviated new drug
applications (ANDAs) held by Able
Laboratories, Inc. (Able Labs), One Able
Dr., Cranbury, NJ 08512. The drug
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
Effective January 19, 2006.
The
applications listed in the table in this
document are no longer marketed, and
Able Labs has requested that FDA
withdraw approval of the applications.
The company has also, by its request,
waived its opportunity for a hearing.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Application No.
Drug
Butalbital, Acetaminophen, and Caffeine Tablets USP, 50 milligrams (mg)/325 mg/40 mg
40–394
Butalbital, Acetaminophen, and Caffeine Tablets USP, 50 mg/500 mg/40 mg
40–402
Phentermine Hydrochloride (HCl) Tablets USP, 37.5 mg
40–403
Phentermine HCL Capsules USP, 30 mg (powder)
40–413
Methocarbamol Tablets USP, 500 mg and 750 mg
40–421
Carisoprodol Tablets USP, 350 mg
40–427
Phentermine HCl Capsules USP, 30 mg (beads)
40–449
Promethazine HCl Suppositories USP, 50 mg
40–464
Hydrocodone Bitartrate and Acetaminophen Tablets USP, 7.5 mg/325 mg and 10 mg/325
mg
40–469
Hydrocodone Bitartrate and Acetaminophen Tablets USP, 7.5 mg/750 mg
40–473
Hydrocodone Bitartrate and Acetaminophen Tablets USP, 10 mg/500 mg
40–474
Hydrocodone Bitartrate and Acetaminophen Tablets USP, 7.5 mg/650 mg
40–476
Hydrocodone Bitartrate and Acetaminophen Tablets USP, 10 mg/650 mg
40–477
Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/500 mg
40–478
Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/325 mg
40–483
Bethanechol Chloride Tablets USP, 10 mg
40–485
Bethanechol Chloride Tablets USP, 25 mg
40–490
Hydrocodone Bitartrate and Acetaminophen Tablets USP, 7.5 mg/500 mg
40–492
Bethanechol Chloride Tablets USP, 5 mg
40–497
Phentermine HCl Capsules USP, 15 mg
40–504
Promethazine HCl Suppositories USP, 12.5 mg and 25 mg
40–509
Bethanechol Chloride Tablets USP, 50 mg
40–529
sroberts on PROD1PC70 with NOTICES
40–390
Methamphetamine HCl Tablets USP, 5 mg
40–539
Theophylline Extended-Release Tablets, 600 mg
40–543
Theophylline Extended-Release Tablets, 400 mg
40–546
Theophylline Extended-Release Tablets, 450 mg
VerDate Aug<31>2005
16:38 Jan 18, 2006
Jkt 208001
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
E:\FR\FM\19JAN1.SGM
19JAN1
]]>Agencies
[Federal Register Volume 71, Number 12 (Thursday, January 19, 2006)]
[Notices]
[Pages 3096-3097]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-529]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Advisory Committee on Immunization Practices: Meeting
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announce the following Federal committee meeting.
Name: Advisory Committee on Immunization Practices (ACIP).
Time and Date: 8 a.m.-6:15 p.m., February 21, 2006.
8 a.m.-5 p.m., February 22, 2006.
Place: Centers for Disease Control and Prevention, 1600 Clifton
Road, NE., Building 19, Room 232, Atlanta, Georgia 30333.
Status: Open to the public, limited only by the space available.
Purpose: The committee is charged with advising the Director,
CDC, on the appropriate uses of immunizing agents. In addition,
under 42 U.S.C. 1396s, the committee is mandated to establish and
periodically review and, as appropriate, revise the list of vaccines
for administration to vaccine-eligible children through the Vaccines
for Children (VFC) program, along with schedules regarding the
appropriate periodicity, dosage, and contraindications applicable to
the vaccines.
Matters To Be Discussed: The agenda will include discussions on
Rotavirus Vaccine which may include a possible VFC Vote; Human
Papillomavirus Vaccine; general recommendations on immunization;
Influenza; Herpes Zoster Vaccine; Tetanus Toxoid, Diphtheria Toxoid,
and Acellular Pertussis (Tdap) Vaccines; and departmental updates.
Agenda items are subject to change as priorities dictate.
For Further Information Contact: Demetria Gardner, Epidemiology
and Surveillance Division, National Immunization Program, CDC, 1600
Clifton Road, NE., (E-61), Atlanta, Georgia 30333, telephone 404/
639-8096, fax 404/639-8616.
[[Page 3097]]
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities for both the CDC and ATSDR.
Dated: January 10, 2006.
Alvin Hall,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. E6-529 Filed 1-18-06; 8:45 am]
BILLING CODE 4163-18-P
